Trial of Optimal Personalised Care After Treatment for Gynaecological cancer (TOPCAT-G): a study protocol for a randomised feasibility trial by Pye, K. et al.
STUDY PROTOCOL Open Access
Trial of Optimal Personalised Care After
Treatment for Gynaecological cancer
(TOPCAT-G): a study protocol for a
randomised feasibility trial
Kirstie Pye1, Nicola Totton1, Nicholas Stuart2, Rhiannon Whitaker3, Val Morrison4, Rhiannon Tudor Edwards5,
Seow Tien Yeo5, Laura J. Timmis5, Caryl Butterworth2, Liz Hall2, Tekendra Rai1, Zoe Hoare1, Richard D. Neal6,
Clare Wilkinson7 and Simon Leeson2*
Abstract
Background: Gynaecological cancers are diagnosed in over 1000 women in Wales every year. We estimate that this is
costing the National Health Service (NHS) in excess of £1 million per annum for routine follow-up appointments alone.
Follow-up care is not evidence-based, and there are no definitive guidelines from The National Institute for Health and
Care Excellence (NICE) for the type of follow-up that should be delivered. Standard care is to provide a regular medical
review of the patient in a hospital-based outpatient clinic for a minimum of 5 years. This study is to evaluate the
feasibility of a proposed alternative where the patients are delivered a specialist nurse-led telephone intervention
known as Optimal Personalised Care After Treatment for Gynaecological cancer (OPCAT-G), which comprised of a
protocol-based patient education, patient empowerment and structured needs assessment.
Methods: The study will recruit female patients who have completed treatment for cervical, endometrial,
epithelial ovarian or vulval cancer within the previous 3 months in Betsi Cadwaladr University Health Board
(BCUHB) in North Wales. Following recruitment, participants will be randomised to one of two arms in the trial
(standard care or OPCAT-G intervention). The primary outcomes for the trial are patient recruitment and attrition
rates, and the secondary outcomes are quality of life, health status and capability, using the EORTC QLQ-C30, EQ-
5D-3L and ICECAP-A measures. Additionally, a client service receipt inventory (CSRI) will be collected in order to
pilot an economic evaluation.
Discussion: The results from this feasibility study will be used to inform a fully powered randomised controlled
trial to evaluate the difference between standard care and the OPCAT-G intervention.
Trial registration: ISRCTN45565436.
Keywords: Gynaecological cancer follow-up, Nurse-led telephone intervention, Feasibility, Randomised controlled
trial, Quality of life
* Correspondence: linandsie@googlemail.com
2Betsi Cadwaladr University Health Board, Bangor, UK
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pye et al. Pilot and Feasibility Studies  (2016) 2:67 
DOI 10.1186/s40814-016-0108-5
Background
In the UK, gynaecological cancers including endomet-
rial (c. 8500 per year), ovarian (c. 7000 per year), cer-
vical (c. 3000 per year) and vulval (c. 1200 per year)
cancer are retrospectively the fourth, fifth, twelfth, and
twentieth most common cancer sites in women [1–4].
Over 1000 females are diagnosed and treated with gy-
naecological cancers each year in Wales (ovarian = 365,
uterine = 539, cervical = 164) [5]. Three North Wales
hospitals comprising Betsi Cadwaladr University Health
Board (BCUHB) (Ysbyty Gwynedd, Ysbyty Glan Clwyd,
and Ysbyty Maelor) serve a population of approximately
678,000 people [6], with 92 ovarian cancer, 107 endo-
metrial cancer and 35 cervical cancer newly diagnosed
in 2014 [7].
Aims of follow-up
The aims of follow-up care include the management of
patients’ physical and psychological morbidity and the
prevention or early detection of local recurrence, distant
metastases or appearance of second cancers [8, 9].
Follow-up care is routine for women who have com-
pleted treatment for gynaecological cancer but is not
evidence-based. Currently, there is no agreement as to
what follow-up care is effective, and there are no guide-
lines from The National Institute for Health and Care
Excellence (NICE) as to what form or frequency of
follow-up is appropriate after treatment for gynaeco-
logical cancer.
Standard approach to follow-up
Following completion of treatment for gynaecological can-
cer, the traditional medical practice is to regularly review
the patient in a hospital-based, outpatient clinic over a
period of years. These regular reviews occur according to
a locally or regionally agreed schedule for at least 5 years
after completion of treatment. In addition to clinical re-
view, patients may have blood tests, scans or other tests as
required. Multiple unproven assumptions lie behind this
standard approach to gynaecological cancer follow-up;
one being that it will benefit the patient by detecting re-
currence early, thus allowing effective treatment and im-
proving survival, or alternatively will offer reassurance to
the patient that all is well. There is however little evidence
to support this approach. In general, early detection of re-
currence is unlikely to improve survival if there is no
intervention capable of producing a cure [10]. For the ma-
jority of gynaecological cancers, any treatment for recur-
rence is palliative and not curative. Whilst a few
retrospective studies suggest that survival was improved
when recurrent cervical or endometrial cancer was de-
tected at routine follow-up rather than when symptoms
develop [11–13], the majority of patients relapse with
symptoms that would prompt reassessment even if the
patient was not on routine review [14–17]. A randomised
controlled trial (RCT) in ovarian cancer that assessed the
value of detecting relapse early by using serum CA125
measurements as part of routine follow-up confirmed that
whilst the test was able to detect pre-symptomatic recur-
rence, this did not lead to any survival benefit. It did how-
ever lead to an inferior quality of life due to further
chemotherapy provision and more treatment-related mor-
bidity [18]. This study again raises doubts about the value
of detecting pre-symptomatic recurrence.
Patients may also receive false reassurance (when
follow-up finds ‘no symptoms’) or they may wait for their
next routine appointment to disclose symptoms [19] thus
possibly delaying detection and appropriate symptom
management. Furthermore, there is evidence that
hospital-based, medical follow-up fails to address many of
the broader needs that patients have following treatment
for gynaecological cancers. Patients commonly report
problems with anxiety and depression [20] and reduced
health-related quality of life (QoL) [21], with specific prob-
lems including the physical effects of treatment such as
distressing disturbance of bowel and bladder function,
sexual relations and relationships, psychological health
and employment problems [22, 23]. These issues are
reflected in studies of patient-expressed needs. Female
cancer patients tend to express more needs than male
cancer patients and report less satisfaction with support
generally [24, 25]. Gynaecological cancer patients have re-
ported a high level of need for detailed information, infor-
mation regarding how best to recover from surgery or to
avoid recurrence and information regarding physiological
and psychological issues [24, 26, 27]. There is evidence
that doctors in routine follow-up clinics often fail to iden-
tify such problems and, if they do, they fail to address
them effectively [28, 29].
Finally, the standard approach to follow-up burdens
the health service with significant costs and chal-
lenges. The increasing numbers of patients who have
received treatment for gynaecological cancer in con-
junction with rising survival rates mean that the
number of patients on follow-up is rising. A signifi-
cant amount of medical, nursing and administrative
time is spent on arranging and undertaking poten-
tially unnecessary medical reviews. The unit cost for
a non-admitted consultant-led, face-to-face, follow-up
appointment in gynaecology oncology for the year
2014–2015 was £168 [30]. We estimate that in Wales,
the National Health Service (NHS) cost of these rou-
tine follow-up appointments, excluding the cost of
any tests ordered, is in excess of £1 million per
annum based on current survival rates and national
follow-up policies. This is in addition to any societal
costs such as time taken from work to attend clinics
and additional childcare costs.
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Alternative approaches to follow-up
In response to these challenges, a range of additional,
alternative or supplementary approaches have been de-
veloped. These include risk-stratified care pathways,
nurse-led clinics, telephone follow-up, reduced fre-
quency of follow-up and remote surveillance strategies
where biomarker or radiological follow-up is key. The
National Cancer Survivorship Initiative [31] recom-
mends a stratified approach to cancer follow-up care as
opposed to the current traditional pathway. The NHS
in England is piloting this risk-stratified approach that
divides cancer patients into three groups: complex and
requiring continued hospital care; shared care, for pa-
tients that require hospital care supplemented by edu-
cation and support; and a self-care group that can be
discharged from routine hospital follow-up [32]. How-
ever, the criteria for these groups are not yet fully de-
fined and neither is the proportion of patients that will
fall into each. Furthermore, there is as yet no evidence
that this approach is superior to standard care or is the
best alternative. We have recently undertaken a na-
tional survey of clinical practice in follow-up in all gy-
naecological cancers [33] which reported that a wide
range of follow-up approaches are used across the UK
despite there being little evidence that they lead to bet-
ter outcomes for patients or are more cost-effective. Al-
though the networks reported a wide range of practice
in relation to tests and frequency of review, the survey
confirmed that hospital-based, medical review remains
the standard approach. A minority used nurse-led or
telephone follow-up, and general practitioners (GPs)
were rarely involved in routine care.
We propose an approach that aims to provide nurse-
led telephone follow-up care for patients. Investigations
into patterns of post-treatment cancer follow-up should
assess recovery from treatment toxicity and social and
psychological rehabilitation as well as health economics
and the detection of relapse. Care should also be indivi-
dualised so that patients can have the information they
need as well as having their individual problems identi-
fied and managed. There is a pressing need for the NHS
to develop patterns of care for patients who have had
treatment for cancer that will address their needs, maxi-
mise their QoL and allow timely diagnosis of relapse yet
uses NHS resources in a cost-effective manner. It is also
important to convince patients, doctors and health ser-
vice managers that this new approach can be adopted
without any adverse effect on survival of patients.
Purpose and scope
This study will evaluate the feasibility of a nurse-led
needs assessment in the gynaecology cancer setting in
North Wales and its utility to health care professionals
when making decisions about supportive care, compared
to disease- and site-matched patients not receiving the
nurse-led needs assessment. The nurse-led intervention
will be known as Optimal Personalised Care After Treat-
ment for Gynaecological cancer (OPCAT-G) and will
comprise patient education, patient empowerment and
protocol-based, structured needs assessment undertaken
with Gynae Oncology clinical nurse specialists (CNSs)
by telephone. Patients will receive an initial structured
telephone interview with a gynaecological CNS and a
booklet including information on symptoms of recur-
rence and possible long-term physical and psychological
side-effects of treatment. Information will also be given
to patients on how they can contact the clinical team if
they have concerns or symptoms; otherwise, they will re-
ceive routine telephone contact 6 months later. The tele-
phone follow-up will involve a structured interview
whereby patients’ unmet needs will be identified and pa-
tients will receive appropriate referral(s). The new ap-
proach will maintain regular contact with patients but
will not involve routine hospital, outpatient attendance.
The aim of this follow-up programme is to manage any
long-term effects from treatment, to reassure the patient
that the cancer remains in remission and if relapse oc-
curs, to detect and treat it early.
This protocol falls within a larger body of work which
includes a national survey relating to current practice of
follow-up for gynaecological cancer patients in the UK
[30], a BCUHB wide audit (headed by SL) of gynaeco-
logical cancer patients to establish key parameters in rela-
tion to recurrence and a small feasibility trial of a short-
form needs assessment tool developed by one co-author
(VM) and colleagues. Funding from Tenovus Cancer Care
has been received for a Ph.D. student (LT, supervised by
RTE, NS, VM) to explore work relating to patient and
caregivers’ perspectives and preferences for different
models of follow-up care [34]. Finally, we are currently
conducting a systematic literature review to provide an
up-to-date evaluation of the available evidence for the dif-
ferent strategies of follow-up after endometrial and vulval
cancer. This body of work aims to show the wide applic-
ability of the proposed intervention, whilst using this
study as an exemplar of the methodology.
This study will focus on gynaecological cancer but will
link with similar studies being developed in North Wales
that will look at other exemplars, particularly prostate
cancer (TOPCAT-P; ISRCTN34516019). The studies will
be independent but will share expertise and co-
investigators to develop a body of expertise relating the
clinical research in this area.
Methods/design
Aim
The primary aim of the current study is to evaluate the
feasibility of conducting a randomised trial comparing
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nurse-led telephone follow-up with standard, hospital-
based, medical follow-up. Feasibility will be determined
by the ability to recruit and retain patients to the study
the ability to collect regular data and to evaluate the ac-
ceptability of implementing this new intervention.
The secondary aim of this feasibility study is to gain
knowledge of standard deviations and effect sizes on the
study outcome measures to inform the power calcula-
tion for a future full trial.
The final aim is to pilot the statistical and health eco-
nomics analysis that would be required within a future
full trial that will ultimately determine the effectiveness
and cost-effectiveness of the new nurse-led telephone
follow-up approach.
Design
The current study will be a parallel-group randomised
controlled feasibility trial design comparing nurse-led
intervention (treatment group) with standard care (con-
trol group) to assess recruitment and retention rates and
acceptability of randomisation and to inform the sample
size calculation for a future trial.
Participants
Inclusion criteria
We propose to recruit a cohort of female patients who
have completed treatment for cervical, endometrial, epi-
thelial ovarian, or vulval cancer within the last 3 months
in BCUHB in North Wales. Patients who have com-
pleted treatment for fallopian tube and primary periton-
eal carcinoma will also be included. The cohort will be
identified through the regional gynaecological cancer
multidisciplinary team meeting (MDT) records and will
consist of patients who are considered fit for taking part
in the trial and able to give informed consent, as
assessed by the MDT. Patients may have received sur-
gery, chemotherapy, radiotherapy or a combination of
these. At the time of entry, patients in the view of their
treating consultant will not have a definite need for con-
tinued hospital-based care.
Exclusion criteria
Patients having had treatment for sarcoma, germ cell
tumour, borderline tumours or choriocarcinoma will be
excluded as these women tend to require specific and/or
more intense follow-up often with serial imaging or
tumour markers. Patients requiring ongoing treatment
will also not be included in the study. The study will not
include patients who do not have the capacity to give in-
formed consent or who are deemed to be unable to take
part in the trial (e.g. severe learning/mental disability, se-
vere mental health problems). Patients who are not able
to understand Welsh or English will also be excluded.
Sample size
We estimate 30% will not fit the inclusion criteria
whilst an unknown proportion of the remainder will
not enter the study, either through not wishing to
consent or for other reasons. The extent of patient
acceptability is unknown but for planning purposes,
we will assume 50% acceptance. Assuming a through-
put of approximately 150 newly diagnosed cases, we
hope to randomise 50 participants from the recruiting
centres into the study during a period of 6 months. It
is thought this would be sufficient to inform a sample
size of a future full trial [35] and enable a reasonably
diverse group to fully assess the acceptability of the
trial.
Recruitment
All patients will be recruited from three hospitals in the
North Wales Cancer Network: Ysbyty Gwynedd, Ysbyty
Glan Clwyd, and Ysbyty Maelor. The research nurse and
three clinical nurse specialists (CNSs) will identify
women from the hospital databases, in line with the in-
clusion and exclusion criteria above. Eligible patients will
be approached by the clinic medical team and/or by the
research nurse/CNS and will be invited to take part in
the study. Patients will be given a participant informa-
tion sheet at their end-of-treatment visit and will have
until their follow-up appointment to consider the study
(usually around 6 weeks), and those who would like to
participate will have the opportunity to contact the re-
search nurse by phone or email for more information
before their follow-up appointment. Patients will be in-
formed that if they agree to participate, they will be ran-
domly assigned to one of the two treatment groups,
both receiving slightly different modes of follow-up sup-
port. After agreeing to take part in the study, patients
will give written consent at their 3-month routine
follow-up appointment.
Randomisation
Following their 3-month appointment, consenting pa-
tients will complete the baseline measures (see below)
then be randomised at the end of the 3-month review
appointment. Patients will be randomised on a 1:1 ratio
by the North Wales Organisation for Randomised Trials
in Health (NWORTH) using a dynamic, independent,
secure, web-based, randomisation procedure that can be
accessed 24 h a day [36]. Patients will be randomised to
one of the two arms of the study: standard care or
nurse-led intervention. Site and disease type will be in-
cluded as stratification variables. The participants, re-
search nurse, CNSs and trial management will be
unblinded during this trial. All other members of the
team, especially the trial statistician, will remain blinded.
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Standard care
After patients have been allocated to the standard care
arm of the study, they will be informed about the next
part of the study and their 6- and 9-month appoint-
ments scheduled. Patients randomised to standard care
will continue to have their usual hospital-based doctor-
led medical reviews (at 6 and 9 months post-treatment
conclusion) and will be followed up according to an
agreed protocol with the regional gynaecological cancer
MDT and representing current practice. This will in-
clude an agreed protocol on further blood tests and
scans if considered appropriate to routine follow-up.
In addition to their usual follow-up appointments,
patients will be asked to complete a set of outcome
questionnaires at baseline (following consent, but
prior to randomisation), with assistance from the re-
search nurse or CNS at the 3-month follow-up ap-
pointment. Patients will then be asked to complete
the same set of outcome measures at the end of each
of their follow-up appointments. If this is not possible,
then the research nurse will send the questionnaires by
post for completion and return in a self-addressed, pre-
stamped envelope.
Nurse-led intervention
Patients in the intervention group will not attend the
hospital for their usual follow-up appointments but will
receive a nurse-led telephone follow-up intervention,
known as Optimal Personalised Care After Treatment
for Gynaecological cancer (OPCAT-G). After patients
have been allocated to the nurse-led intervention arm of
the study, the research nurse or CNS will inform pa-
tients of their allocation. The CNS will give the patients
an information booklet at the end of their 3-month
medical review and will guide the patient through the
sections of the booklet. The information booklet will in-
clude information on patterns of relapse, possible warn-
ing symptoms and how to respond to these. Information
will also be given on possible long-term physical and
psychological side-effects of treatment and how these
can be managed. Information will also be given to pa-
tients on how they can contact the clinical team if they
have concerns or symptoms. Patients will receive treat-
ment and diagnosis-specific supplementary leaflets at-
tached to the booklet. The CNS will also give patients a
set of needs assessment measures, including:
a) Macmillan Concerns Checklist [37]
The Macmillan Concerns Checklist addresses 23
physical concerns; 9 practical concerns; 3 family/
relationship concerns; 9 emotional concerns; 3
spiritual or religious concerns; and 9 lifestyle or
information needs. Patients are asked to tick a box for
any problems that have caused concern during the
previous week or to leave the box blank if it does not
apply to them.
b) CancerCAN-22 [24, 38, 39]
This is a multi-domain needs assessment tool
that measures unmet needs across 22 items (12
psychosocial needs items and 10 treatment and care
items). Items are either met, unmet or never had/not
applicable; then scored for salience if unmet on a 0–3
Likert scale (no importance, low importance, medium
importance and high importance).
c) Distress thermometer
This is a reliable measure of patients’ distress and
concerns and is widely used in cancer studies [40].
It has accepted cut-offs indicative of clinical levels
of global distress.
Patients will be asked to complete the needs assess-
ment measures prior to a scheduled telephone call from
the CNS. Patients will receive a scheduled telephone call
within 4 weeks of randomisation and will be notified of
their scheduled telephone call date and time at the end
of their 3-month medical review. Patients will also re-
ceive a letter confirming the date and time of their
scheduled telephone call.
The scheduled telephone call will involve a structured
interview with the CNS. Patients will be asked about
their general wellbeing and about any gynaecological
symptoms experienced. Any identified needs or concerns
from the three needs assessment measures will be dis-
cussed. Patients in whom problems or unmet needs are
identified will be evaluated and directed to the most ap-
propriate source of help. This could include a patient
self-help group, their general practitioner, or hospital re-
view by the gynaecology, oncology or clinical psychology
team. These additional appointments would be facili-
tated by the CNS who would ensure appropriate com-
munication regarding the reasons for referral. This
information, including advice and follow-up suggestions,
will be recorded using a case note sheet. Patients re-
ferred for further hospital review will be discharged to
continue telephone review once their immediate prob-
lem has been assessed and treated or resolved. Patients
will receive additional copies of the needs assessment
measures by post. Patients will be told that if they have
any problems between telephone calls, they should
complete their assessments and contact the CNS. Patients
will be encouraged to report problems promptly with
these concerns addressed in the same structured way.
Patients will then receive another scheduled tele-
phone call at 9 months post-treatment. Patients will
receive a letter confirming the date and time of their
telephone call appointment by post. Patients will also
receive the three needs assessment measures by post
and will be asked to complete them prior to their
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scheduled telephone call from the nurse. The tele-
phone contact will again include a structured inter-
view and any identified needs or concerns will be
discussed following the same structure of the first
telephone call interview.
In addition to the nurse-led intervention, patients will
be asked to complete the same set of outcome question-
naires as patients in the standard care arm. The outcome
questionnaires will be completed at baseline (prior to
randomisation) with assistance from the research nurse
or CNS at the 3-month follow-up appointment. Patients
will receive the same set of outcome questionnaires by
post at 6 months post-treatment and within a week of
their 9-month telephone follow-up and will be asked to
return them in a self-addressed, pre-stamped envelope.
For this study, we will consider the study endpoint to
be the 9 months post-treatment data collection. After
the 9-month data collection point, the intervention and
control arm patients will continue with follow-up care
as the clinician advises and is available to the local
service.
CONSORT Diagram
The CONSORT Diagram, which will be used to illus-
trate recruitment and loss during the study, can be
found in Fig. 1. For a further detailed breakdown of the
patient involvement in the study, Fig. 2 shows the
SPIRIT flowchart of the trial.
Measures
Primary outcome measures
The primary outcome measures of the feasibility trial
will be:
Fig. 1 CONSORT Diagram for TOPCAT-G feasibility study
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a) Patient recruitment rate
This will be calculated from the total number of
eligible patients invited to take part in the study and
the number of patients giving written consent to
participate in the study.
b) Patient attrition rate
This will be calculated from the number of patients
who gave written consent and the number of
patients who have completed any measures,
regardless of their completion rate.
Secondary outcome measures
A single booklet of outcome questionnaires will be pro-
vided to all trial participants at baseline and 6 and
9 months post-treatment. These are as follows:
a) EORTC QLQ-C30
This is a validated measure to assess the quality of
life of cancer patients [41]. It comprises a 30-item
questionnaire incorporating five functional scales
(physical, role, cognitive, emotional and social), three
symptom scales (fatigue, pain and nausea and vomit-
ing), a global health status/quality of life scale and a
number of single items assessing additional
symptoms commonly reported by cancer patients
and perceived financial impact of the disease.
b) EQ-5D-3L
This is a validated generic, health-related,
preference-based measure comprising five domains:
mobility, self-care, usual activities, pain and discom-
fort and anxiety and depression. Each domain has
three levels (no problems, some problems and a lot
of problems). The EQ-5D-3L scoring system defines
243 possible health states. The questions are com-
plemented by a visual analogue scale (VAS), on
which respondents are asked to indicate their
current health [42].
c) ICECAP-A (ICEpop CAPability measure for Adults)
This is a measure of capability for the general adult
population [43]. The ICECAP-A covers five attri-
butes of wellbeing: attachment, stability, achieve-
ment, enjoyment and autonomy.
d) Client Service Receipt Inventory (CSRI)
This is an adapted version of a standardised
measure using self-report service user data to evalu-
ate and cost service use, including all GP visits and
unscheduled secondary care in both arms of the
study [44, 45].
Fig. 2 CONSORT Diagram for TOPCAT-G feasibility study
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Additional data to be captured will include the
following:
e) Patient demographics, cancer type and stage, type of
treatment received and co-morbidity at baseline
(from medical records and patient confirmation).
f ) Data on the pattern, timing and method of detection
of relapse and on survival (recorded using a Serious
Adverse Events form).
We anticipate that on average patients would
complete all questionnaires in about 20 min on each
occasion.
The number of patients offered the study will be
logged to identify the proportion of patients that decline
to take part. Patients who decline to consent will be
asked if they would be willing to provide any reason(s)
why they preferred not to take part.
Data will aim to be collected from all willing partici-
pants, even in the case of a withdrawal or non-
compliance with the intervention.
Data collection/storage
Data collection, cleaning and analysis will be undertaken
by NWORTH using standard, secure, anonymous proce-
dures for handling patient data. The fully auditable
MACRO data management system will be used to en-
sure best practice. The health economics and patients’
demographic data will be transferred from NWORTH to
CHEME (Centre for Health Economics and Medicines
Evaluation) for further analysis.
Statistical methods
Descriptive statistics will be reported, including clinical
and demographic characteristics of those recruited. To
assess the feasibility of a full RCT, the recruitment and
retention rates will be calculated. A future full RCT will
be considered feasible if the recruitment rate is at least
50% and retention rate is no less than 50%. Additionally,
the patient eligibility rate and questionnaire completion
rates will be calculated to provide further evidence for
the appropriateness of a full trial and associated
measures.
Exploratory analysis will also be conducted around the
assessments of QoL with the purpose of estimating key
parameters for powering the main RCT but not to pro-
vide definitive results for the study. Effect sizes of the
differences in final scores calculated from the EORTC
QLQ-C30 will be calculated between the groups as ran-
domised for the study endpoint. The effect size will be
used to inform future sample size calculations for a lar-
ger, multi-centre RCT.
Health economics
An exploratory health economic analysis will be con-
ducted to assess the feasibility of answering the required
research questions within a full RCT, but not to provide
definitive results for the study at this stage. Descriptive
statistics will be performed to assess the responses of the
self-reported health service use, EQ-5D-3L and ICECAP-
A and the level of completeness for EQ-5D-3L and
ICECAP-A in both arms of the study; this will allow us to
explore as to how well the self-administered question-
naires perform in this patient population group. The
strength of the relationship between EQ-5D-3L index
score and ICECAP-A score will be explored using
Pearson’s Product Moment Correlation Coefficient. An
exploratory cost-effectiveness analysis will be undertaken
from a multi-agency perspective to explore the cost-
effectiveness of a ‘nurse-led’ intervention compared to
standard care; this will help power economic analysis
alongside a future full trial.
Trial management plan
A trial working group (WG) consisting of individuals re-
sponsible for the effective day-to-day running of the trial
will meet on a monthly basis. The WG will be chaired
by the chief investigator (CI). The WG will report regu-
larly to the steering group (SG) to highlight any areas of
difficulty.
The trial will be managed by a SG, chaired by one of
the co-applicants. The SG will meet at least three times
per year to oversee the overall running of the trial and
to ensure timely progress with trial development, imple-
mentation and reporting. It will comprise the CI and co-
applicants.
Two patient representatives from the North Wales
Cancer Forum Group will be invited to attend SG meet-
ings in order to contribute to discussions regarding
study recruitment methods and materials, including the
patient information sheets and consent materials and
the intervention protocol. This group will also benefit
the project team in terms of advising as to the appropri-
ate interpretation and dissemination of findings and to
how best take forward the findings into development of
the ensuing RCT protocol.
A Data Monitoring and Ethics Committee (DMEC)
will independently monitor the data and quality assur-
ance of the study. This will consists of an independent
chair, statistician and expert in the field.
Day-to-day running and co-ordination of the trial
will be undertaken by an appropriately experienced
research officer employed by NWORTH. This work
will be supported by the research nurse, a new ap-
pointment arising from the collaboration between
Health and Care Research Wales and BCUHB to sup-
port the portfolio of such studies within BCUHB.
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Both organisations have well-developed research gov-
ernance procedures and have joint standard operating
procedures (SOPs) for research. All research staff will
receive Good Clinical Practice training, SOP training
and any further task-specific training identified. Full
training details will be maintained in individual staff
training matrices as per SOP.
Reports and dissemination
Findings from this study will be presented via posters
and oral presentations at regional and national meetings
where oncology doctors, specialist nurses and health ser-
vice managers would be present. This would include
specialist meetings relating to gynaecological oncology,
medical oncology, health psychology/psycho-oncology
and health economics.
Papers will be submitted to relevant international jour-
nals such as International Journal of Gynecological On-
cology, British Journal of Obstetrics and Gynaecology,
Lancet Oncology and British Journal of Cancer.
Preparation of the protocol for a national randomised,
multi-centre trial comparing OPCAT-G with standard
care would be a key output from this work. Publications
are also expected from the work of the Tenovus Ph.D.
student regarding patients, carers and health care profes-
sionals preferences for gynaecological cancer follow-up
care.
Discussion
The TOPCAT-G study will evaluate the feasibility of
completing a full, definitive RCT that would assess the
potential benefits of nurse-led telephone follow-up for
gynaecological cancer patients compared with current
follow-up care comprised of regular outpatient appoint-
ments. Feasibility for the study will be judged using pa-
tient recruitment and attrition rates. The study will also
provide indications on the suitability of the outcome
measures and will pilot the proposed statistical analysis
plan and also a cost-effectiveness analysis plan which
would be an essential part of a full RCT. The results
found from the feasibility study will also be used to in-
form the sample size of a future RCT.
A potential operational issue for the study might be in
finding an appropriate space for each of the CNSs to
complete their telephone follow-ups with the partici-
pants. Gaining information on issues such as this will be
a vital part of shaping the design of a future RCT. An
unknown part of the study is the amount of time each of
the telephone follow-ups will take for the CNSs to
complete; this will be collected and collated at the end
of the feasibility study to help more accurately inform a
future RCT.
Trial status
The TOPCAT-G study started in July 2014, screening
began in September 2015 giving a recruitment period of
November 2015 to the end of April 2016. Follow-ups
will continue until October 2016, and the trial is due to
end in January 2017.
Abbreviations
BCUHB: Betsi Cadwaladr University Health Board; CHEME: Centre for Health
Economics and Medicines Evaluation; CI: Chief Investigator; CNS: Clinical
nurse specialist; CSRI: Client Service Receipt Inventory; EQ-5D-3L: EuroQoL-5
dimensions-3 levels; GP: General Practitioner; HR-QoL: Health-related quality
of Life; ICECAP-A: ICEpop CAPability measure for Adults;
MDT: Multidisciplinary team meeting; NHS: National Health Service; NICE: The
National Institute for Health and Care Excellence; NISCHR CRC: National
Institute for Social Care and Health Research Clinical Research Centre;
NSAG: National Strategic Advisory Group; NWORTH: North Wales
Organisation for Randomised Trials in Health; QoL: Quality of life;
R&D: Research and Development; RCT: Randomised controlled trial;
SG: Steering group; SOP: Standard operating procedure; TOPCAT-G: Trial of
Optimal Personalised Care After Treatment for Gynaecological cancer;
TOPCAT-P: Trial of Optimal Personalised Care After Treatment for Prostate
cancer; VAS: Visual analogue scale; WG: Working group
Acknowledgements
The authors would like to thank Jane Evans and Sharon Manning for their
roles in patient recruitment and their ongoing support in completing the
intervention.
Funding
The TOPCAT-G study is funded and sponsored by the Betsi Cadwaladr
University Health Board (BCUHB), Ysbyty Gwynedd, Penrhosgarnedd Bangor,
LL57 2PZ.
Authors’ contributions
KP contributed to the study design, the trial management (July 2014–
October 2015), the preparation and writing of the study protocol and the
implementation of the study. NT contributed to the preparation of the study
protocol, the statistical analysis and the drafting of the manuscript. NS
contributed to the study concept, the study design, the development of the
intervention, the preparation of the study protocol and the review of the
manuscript. RhW is a patient representative and contributed to the study
funding, the study concept, the study design, the development of the
intervention, the preparation of study protocol and the review of manuscript.
VM contributed to the study design, the development of the intervention,
the preparation of the study protocol, the health psychology oversight and
the review of manuscript. RTE contributed to the study design, the
development of the intervention, the preparation of the study protocol, the
health economic oversight, the review of the manuscript. STY contributed to
the preparation of the study protocol, the health economic analysis, and the
review of the manuscript. LJT is a Tenovus Ph.D. student and contributed to
the preparation of the study protocol and the review of the manuscript. CB:
Preparation of study protocol, recruitment and screening of participants, data
collection, review of manuscript. LH contributed to the preparation of the
study protocol, the recruitment and screening of the participants, the
implementation of the intervention, the data collection and the review of
the manuscript. TR contributed to the trial management (October 2015–
March 2016), the preparation of the study protocol and the review of the
manuscript. ZH contributed to the statistical oversight and the review of the
manuscript. RDN contributed to the study design, the preparation of the
study protocol and the review of the manuscript. CW contributed to the
study design, the preparation of the study protocol and the review of the
manuscript. SL is chief investigator and contributed to the study concept,
the study design, the development of the intervention, the preparation of
the study protocol, the study oversight and the review of the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Pye et al. Pilot and Feasibility Studies  (2016) 2:67 Page 9 of 11
Consent for publication
Not applicable
Ethics approval and consent to participate
Ethical approval was granted by NRES Committee London - South East on
the 22nd of May 2015 (Ref: 15/LO/0716, IRAS number: 167879). R&D
(Research and Development) was submitted for approval on the 2nd of June
2015 and granted on the 26th of August 2015 by the R&D internal panel
board, Betsi Cadwaladr University Health Board. All protocol amendments
will be re-submitted for approval.
Protocol version
This paper is from protocol V2 dated 2 July 2015.
Author details
1North Wales Organisation for Randomised Trials in Health (NWORTH),
IMSCaR, COHABS, Bangor University, Bangor, UK. 2Betsi Cadwaladr University
Health Board, Bangor, UK. 3Whitaker Research Ltd., Bangor, UK. 4School of
Psychology, COHABS, Bangor University, Bangor, UK. 5Centre for Health
Economics and Medicines Evaluation, IMSCaR, COHABS, Bangor University,
Bangor, UK. 6Leeds Institute of Health Sciences, University of Leeds, Leeds,
UK. 7North Wales Centre for Primary Care Research, COHABS, Bangor
University, Bangor, UK.
Received: 29 April 2016 Accepted: 8 November 2016
References
1. Cervical Cancer Statistics, Cancer Research UK. Retrieved from: http://www.
cancerresearchuk.org/cancer-info/cancerstats/types/cervix/. Accessed 11
Aug 2014.
2. Uterine Cancer Statistics, Cancer Research UK. Retrieved from http://www.
cancerresearchuk.org/cancer-info/cancerstats/types/uterus/. Accessed 11
Aug 2014.
3. Ovarian Cancer Statistics, Cancer Research UK. Retrieved from http://www.
cancerresearchuk.org/cancer-info/cancerstats/types/ovary/. Accessed 11
Aug 2014.
4. Vulval Cancer Statistics, Cancer Research UK. Retrieved from http://www.
cancerresearchuk.org/cancer-info/cancerstats/types/vulva/. Accessed 11
Aug 2014.
5. Cancer in Wales, Welsh Cancer Intelligence and Surveillance Unit. Retrieved
from http://www.wcisu.wales.nhs.uk/cancer-statistics. Accessed 23 Feb 2016.
6. Betsi Cadwaladr University Health Board. Retrieved from http://www.wales.
nhs.uk/sitesplus/861/page/84723. Accessed 6 Apr 2016.
7. Incidence Trends 2001 - 2014, Welsh Cancer Intelligence and Surveillance
Unit. Retrieved from http://www.wcisu.wales.nhs.uk/officical-statistics-exel-
files-of-trend. Accessed 25 Oct 2015.
8. Follow-up Care After Cancer Treatment, National Cancer Institute. Retrieved
from http://www.cancer.gov/about-cancer/coping/survivorship/follow-up-
care/follow-up-fact-sheet . Accessed 9 May 2010.
9. The Royal Society of Medicine Press. Management of gynaecological cancer.
Effect Health Care Bulletin. 1999;5(3) ISSN: 0965-0288.
10. Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for
patients with epithelial ovarian cancer following completion of primary
treatment. Cochrane Database Syst Rev. 2011;6:CD006119. doi:10.1002/
14651858.CD006119.pub2. Review.
11. Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, et
al. Posttherapy surveillance of women with cervical cancer: an outcomes
analysis. Gynecol Oncol. 2000;78:187–93.
12. Carrara L, Gadducci A, Landoni F, et al. Could different follow-up modalities
play a role in the diagnosis of asymptomatic endometrial cancer relapses?:
an Italian multicentric retrospective analysis. Int J Gynecol Cancer. 2012;
22(6):1013–9. doi:10.1097/IGC.0b013e31825ad3ee.
13. Ueda Y, Enomoto T, Egawa-Takata T, Miyatake T, Yoshino K, Fujita M, et al.
Endometrial carcinoma: better prognosis for asymptomatic recurrences than
for symptomatic cases found by routine follow-up. Int J ClinOncol. 2010;
15(4):406–12.
14. Ansink A, de Barros LA, Naik R, Monaghan JM. Recurrent stage IB cervical
carcinoma: evaluation of the effectiveness of routine follow up surveillance.
Br J Obstet Gynaecol. 1996;103:1156–8.
15. Gerdin E, Cnattingius S, Johnson P, Pettersson B. Prognostic factors and
relapse patterns in early-stage cervical carcinoma after brachytherapy and
radical hysterectomy. Gynecol Oncol. 1994;53:314–9.
16. Kunkler IH, Kerr GR, Ludgate SM. The value of follow-up in stage II
carcinoma of the cervix. Clin Oncol (R Coll Radiol). 1991;3:28–31.
17. Lim KCK, Howells REJ, Evans AS. The role of clinical follow up in early stage
cervical cancer in South Wales. BJOG. 2004;111:1444–8.
18. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC,
et al. MRC OV05; EORTC 55955 investigators. Early versus delayed treatment
of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
Lancet. 2010;376:1155–63. doi:10.1016/S0140-6736(10)61268-8.
19. Olaitan A, Murdoch J, Anderson R, James J, Graham J, Barley V. A critical
evaluation of current protocols for the follow-up of women treated for
gynecological malignancies: a pilot study. Int J Gynecol Cancer. 2001;11:349–53.
20. Norton TR, Manne SL, Rubin J, Hernandez E, Edelson MI, Rosenblum N, et al.
Prevalence and predictors of psychological distress among women with
ovarian cancer. J Clin Oncol. 2004;22:919–26.
21. De Moor JS, De Moor CA, Basen-Enquist K, Kudelka A, Bevers MW, Cohen L.
Optimism, distress, health-related quality of life, and change in cancer
antigen 125 among patients with ovarian cancer undergoing
chemotherapy. Psychosom Med. 2006;678:555–62.
22. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, et al. Long-term
adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008;
18:1183–93. doi:10.1111/j.1525-1438.2007.01167.x. Epub 2008 Jan 22.
23. Penson RT, Wenzel LB, Vergote I, Cella D. Quality of life considerations in
gynaecological cancer. FIGO 26th Annual Report in the Results of Treatment
in Gynaecological Cancer. Int J Gyn Obst. 2006;95(S1):S247–57.
24. Morrison V, Henderson BJ, Zinovieff F, Davies G, Gollins S. Common,
important, and unmet needs of cancer outpatients. Eur J Oncol Nurs. 2012;
16:115–23. doi:10.1016/j.ejon.2011.04.004.
25. Clarke S, Booth L, Velikova G, Hewison J. Social support: gender differences
in cancer patients in the United Kingdom. Cancer Nurs. 2006;29:66–72.
26. Stewart DE, Wong F, Cheung AM, Dancey J, Meana M, Cameron J, Rosen B,
et al. Information needs and decisional preferences among women with
ovarian cancer. Gynecol Oncol. 2000;77(3):357–61.
27. Greimel E, Lahousen M, Dorfer M, Lambauer M, Lang U. Patients’ view of
routine follow-up after gynecological cancer treatment. Eur J Obstet
Gynecol Reprod Biol. 2011;159(1):180–3. doi:10.1016/j.ejogrb.2011.06.027.
28. Carlson LE, Waller A, Mitchell AJ. Screening for distress and unmet needs in
patients with cancer: review and recommendations. J Clin Onc. 2012;30:1160–76.
29. Oshima S, Kisa K, Terashita T, Kawabata H, Maezawa M. Care-seeking
behavior of Japanese gynecological cancer survivors suffering from
adverse effects. BMC Women’s Health. 2013;2013:13(1). doi:10.1186/1472-
6874-13-1.
30. National schedule of reference costs: the main schedule, Department of
Health. Retrieved from https://www.gov.uk/government/publications/nhs-
reference-costs-2014-to-2015. Accessed 12 Feb 2016.
31. Innovation to implementation: stratified pathways of care for people living
with or beyond cancer, National Cancer Survivorship Initiative. Retrieved
from http://www.ncsi.org.uk/wp-content/uploads/howtoguide.pdf. Accessed
10 Sept 2015.
32. Stratification Process, National Cancer Survivorship Initiative. Retrieved from
http://www.ncsi.org.uk/what-we-are-doing/risk-stratified-pathways-of-care/
risk-stratification/. Accessed 10 Sept 2015.
33. Leeson S, Stuart N, Sylvestre Y, Hall L, Whitaker R. Gynaecological cancer
follow-up: national survey of current practice in the UK. Br Med J Open.
2013;3:e002859. doi:10.1136/bmjopen-2013-002859.
34. Budd L, Morrison V, Seale T, Edwards RT. Patients, carers and health care
professionals’ preferences for gynaecological cancer follow-up care: a mixed
method systematic review (protocol). CRD42015016230. PROSPERO.
Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=
CRD42015016230. Accessed 25 Mar 2015.
35. Sim J, Lewis M. The size of a pilot study for a clinical trial should be
calculated in relation to considerations of precision and efficiency. J Clin
Epidemiol. 2012;65(3):301–8.
36. Russell D, Hoare ZSJ, Whitaker R, Whitaker CJ, Russell IT. Generalized
method for adaptive randomization in clinical trials. Stat Med. 2011;30:
922–34.
37. Concerns checklist, National Cancer Survivorship Initiative. Retrieved from
http://www.ncsi.org.uk/wp-content/uploads/NCSI_Concerns_checklist.pdf.
Accesssed 10 Sept 2015.
Pye et al. Pilot and Feasibility Studies  (2016) 2:67 Page 10 of 11
38. Morrison V. Assessing cancer needs: feasibility of implementation. Oral
presentation at the European Health Psychology Society (EHPS) Annual
Conference, Innsbruck; 2014.
39. Morrison V, Holmes M, Gollins S. Unmet needs and the experience of
distress in cancer outpatients. Poster presentation at the BPS Division of
Health Psychology Annual Conference, York; 2014
40. Mitchell A. Pooled results from 38 analyses of the accuracy of the distress
thermometer and other ultra-short methods of detecting cancer-related
mood disorders. J Clin Oncol. 2007;25:4670–81.
41. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for
Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for
use in International Clinical Trials in Oncology. JNCI. 1993;85:365–76.
42. EQ-5D-3L User Guide version 2.0, EuroQol. Retrieved from http://www.euroqol.
org/about-eq-5d/publications/user-guide.html. Accessed 26 Mar 2016.
43. ICECAP-A, University of Birmingham. Retrieved from http://www.
birmingham.ac.uk/research/activity/mds/projects/HaPS/HE/ICECAP/ICECAP-
A/index.aspx. Accessed 26 Mar 2016.
44. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL.
Methods for the economic evaluation of health care programmes (3rd
edition). Oxford: Oxford University Press; 2005.
45 Ridyard CH, Hughes DA, DIRUM Team. Development of a database of
instruments for resource-use measurement: purpose, feasibility, and design.
Value Health. 2012;15:650–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pye et al. Pilot and Feasibility Studies  (2016) 2:67 Page 11 of 11
